
Revolutionizing Neurology with Cutting-Edge Technology
NMTC is revolutionizing brain technology with its advanced ultra-thin electrodes that can interface with more neurons by reducing the size of the contacts. This breakthrough enables more precise communication within the brain, enhancing the potential for diagnosing and treating neurological disorders. Additionally, NMTC's technology offers a minimally invasive approach to back pain treatment, allowing a film electrode to be placed through a needle in the spine to stimulate broader areas without the need for incisions.
This cutting-edge technology is also a game-changer for pharmaceutical companies, as it enables the precise location of specific areas in the brain for the delivery of gene and cell-based therapies, while simultaneously monitoring their effects. No other technology on the market provides this level of precision.
NMTC will be presenting at a prominent pain meeting in late September, where Dr. Sean Li will showcase the technology, calling it "The Next Big Thing."
NMTC vs. Neuralink: A Real Contender in the Neurotech Race
While Neuralink has captured headlines, NMTC is already commercially active. Neuralink is still awaiting FDA clearance, while NMTC has three FDA-cleared products in use at academic centers across the U.S.
With a fraction of the valuation—and actual revenue being generated—NMTC represents a unique opportunity in the neurotech space.
FDA-Approved and Commercially Deployed
This isn’t theoretical technology. NMTC currently has three FDA-cleared products, including the Evo® sEEG and cortical electrode systems, and its OneRF® system for ablation.
These tools are actively being used at some of the nation's top academic hospitals. In April 2025, NMTC submitted a 510(k) for a new indication: ablation of the trigeminal nerve to treat trigeminal neuralgia, a severe and often debilitating facial pain disorder.
Strategic Partnership with a $25 Billion Powerhouse
Since 2020, NMTC has been partnered with Zimmer Biomet—a global leader in surgical and musculoskeletal technology. Zimmer distributes NMTC’s Evo® diagnostic system for epilepsy. In 2025, the relationship expanded, including a $3 million upfront payment and supply agreement, reinforcing Zimmer’s long-term confidence in NMTC’s platform.
Big Moves on the Horizon